EchoNous Secures $60 Million in Funding from Kennedy Lewis Investment Management

EchoNous, the leader in portable AI-guided ultrasound tools and software, announced it has raised $60 million in funding from Kennedy Lewis Investment Management (“Kennedy Lewis”), a leading opportunistic credit manager with a strong track record of supporting innovative life sciences companies.

The investment from Kennedy Lewis combines senior secured debt and equity and builds on the support of KKR, which has been EchoNous’ principal investor since 2015.

Proceeds from the financing will help fuel the commercial launch of Kosmos, EchoNous’ flagship device. Kosmos is the first AI-guided point-of-care ultrasound (POCUS) system to provide diagnostic-quality imaging on par with larger, less portable, and more expensive imaging machines. Kosmos’ system enables systolic heart function assessment, and it is the only handheld POCUS device to offer continuous-wave Doppler capability, a feature with important applications for cardiology. In addition, Kosmos is the only product of its size and in its category to meet HIPAA requirements for data collection, storage, and transmission.

Rich Gumer, Managing Director at Kennedy Lewis and head of the firm’s Life Sciences strategy, said: “We are thrilled to partner with EchoNous on its next phase of growth. EchoNous has an exceptional track record in developing high quality AI-guided ultrasound devices which are more intelligent, accessible, and easier to use. Kosmos’ superior imaging quality, mobility and affordability have the potential to significantly improve patient care and lower healthcare costs which are the core tenets of Kennedy Lewis’ investment ethos in life sciences.”

“This investment marks a turn toward an exciting future for POCUS in which clinical bedside medicine is driven by higher-performance ultrasound technologies that are easy to implement and cost effective,” added Kevin Goodwin, CEO of EchoNous. “To make this vision a reality, we value experienced partners who can see that future as clearly as we do. We could not be happier to have Kennedy Lewis’ support.”

SourceEchoNous

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version